购物车
- 全部删除
- 您的购物车当前为空
Enzaplatovir (BTA-585) 是一种可口服的融合 (fusion) 抑制剂,具有抗病毒活性,可用于研究呼吸道合胞病毒感染和冠状病毒病 (COVID-19) 感染。
Enzaplatovir (BTA-585) 是一种可口服的融合 (fusion) 抑制剂,具有抗病毒活性,可用于研究呼吸道合胞病毒感染和冠状病毒病 (COVID-19) 感染。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 1,980 | 现货 | |
5 mg | ¥ 4,920 | 现货 | |
10 mg | ¥ 7,130 | 现货 | |
25 mg | ¥ 10,600 | 现货 | |
50 mg | ¥ 13,800 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 4,970 | 现货 |
产品描述 | Enzaplatovir (BTA-585) is an orally available fusion inhibitor with antiviral activity for the study of respiratory syncytial virus infections and coronavirus disease (COVID-19) infections. |
别名 | 恩扎托韦, BTA-C585, BTAC585, BTA-585, BTA585, BTA 585 |
分子量 | 377.4 |
分子式 | C20H19N5O3 |
CAS No. | 1323077-89-9 |
Smiles | Cc1nocc1C(=O)N1CCN2C(=O)c3cccn3C[C@]12c1ccc(C)nc1 |
密度 | 1.46 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 150 mg/mL (397.46 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容